Wall Street analysts will be watching closely when Nektar Therapeutics (NASDAQ:NKTR) reports its quarterly earnings next, which is scheduled for Thu 7 Mar (In 23 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.52 per share. In the preceding quarter, the company reportedly generated EPS of -$0.56 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of 61.20%, a profit margin of 59.70% and a gross margin of 97.90%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of Nektar Therapeutics (NASDAQ:NKTR). Most recently, on December 13th, 2018, Goldman Initiated a Buy rating. Before that, on June 11th, 2018, H.C. Wainwright Downgrade to Neutral. H.C. Wainwright Reiterated a Buy rating on June 4th, 2018, Seaport Global Securities Initiated an Buy rating on April 20th, 2018, and Piper Jaffray Resumed a Overweight rating on April 13th, 2018.
At its current price point, combined with the fact that this company has 172.70M shares outstanding, the current market capitalization sits at 7.30B. In the last trading day, 4,079,329 shares of Nektar Therapeutics were traded, which compares to its usual volume of about 2.16M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by -$1.49 in the past five trading days, resulting in a percentage change of -3.41% and a moving average of 44.33. In the past 20 days, its price changed by $0.74 (which is +1.78%) and the stock’s moving average was 43.89. Looking back a full 50 days, shares of NKTR changed by $3.71 (which is +9.62%) and demonstrated a moving average of 39.36.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 62.93%, a 14-day Stochastic %K score of 54.84% and a 20-day Stochastic %K score of 58.50%. Using a similar metric, Nektar Therapeutics (NKTR) shares showed a Stochastic %D of 71.18% over the past 9 days, a Stochastic %D score of 57.16% over the last 14 days, and a 20-day Stochastic %D of 65.61%. Meanwhile, this stock’s MACD Oscillator was 0.89 over the past 9 days, 1.05 over the past two weeks, and 0.61 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $42.26 level. Over the past 12 months, this stock has experienced a high price of $111.36 and a low of $29.22. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
Fidelity Management Research Co sold more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from Nektar Therapeutics (NASDAQ:NKTR) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 23,088,888 shares of the company’s stock following the subtraction of -1,765,147 to this investor’s holdings during the three-month period. This share count represents that Fidelity Management Research Co now held 13.34% stake in Nektar Therapeutics (NKTR)’s shares.
Just in the most recent trading day, Nektar Therapeutics (NASDAQ:NKTR) experienced a high price of $45 and low point of $41.39. At the end of the last trading session, this stock was at 42.26 per share, following a loss of -$1.55, or -8.82% during the full day.